617 related articles for article (PubMed ID: 28258191)
1. Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.
Wu Q; Wang Q; Mao G; Dowling CA; Lundy SK; Mao-Draayer Y
J Immunol; 2017 Apr; 198(8):3069-3080. PubMed ID: 28258191
[TBL] [Abstract][Full Text] [Related]
2. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
Front Immunol; 2018; 9():1097. PubMed ID: 29896193
[TBL] [Abstract][Full Text] [Related]
3. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L
Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150
[TBL] [Abstract][Full Text] [Related]
4. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
[TBL] [Abstract][Full Text] [Related]
5. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
[TBL] [Abstract][Full Text] [Related]
6. Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment.
Mansilla MJ; Navarro-Barriuso J; Presas-Rodríguez S; Teniente-Serra A; Quirant-Sánchez B; Ramo-Tello C; Martínez-Cáceres EM
CNS Neurosci Ther; 2019 Sep; 25(9):995-1005. PubMed ID: 31066225
[TBL] [Abstract][Full Text] [Related]
7. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
Li R; Rezk A; Ghadiri M; Luessi F; Zipp F; Li H; Giacomini PS; Antel J; Bar-Or A
J Immunol; 2017 Jan; 198(2):691-698. PubMed ID: 27974457
[TBL] [Abstract][Full Text] [Related]
8. Existence of Th22 in children and evaluation of IL-22 + CD4 + T, Th17, and other T cell effector subsets from healthy children compared to adults.
Shen E; Wang M; Xie H; Zou R; Lin Q; Lai L; Li F; Liang Z; Xu Y; Zhou M
BMC Immunol; 2016 Jun; 17(1):20. PubMed ID: 27338754
[TBL] [Abstract][Full Text] [Related]
9. Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis.
Holm Hansen R; Højsgaard Chow H; Christensen JR; Sellebjerg F; von Essen MR
Mult Scler Relat Disord; 2020 Jan; 37():101451. PubMed ID: 31675639
[TBL] [Abstract][Full Text] [Related]
10. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
[TBL] [Abstract][Full Text] [Related]
11. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].
Shmidt TE
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100
[TBL] [Abstract][Full Text] [Related]
12. The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis.
Tahvili S; Zandieh B; Amirghofran Z
Int J Dermatol; 2015 Jul; 54(7):e254-60. PubMed ID: 26108267
[TBL] [Abstract][Full Text] [Related]
13. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
Yadav SK; Soin D; Ito K; Dhib-Jalbut S
J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593
[TBL] [Abstract][Full Text] [Related]
14. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
16. Immunomonitoring measures in relapsing-remitting multiple sclerosis.
Matsui M; Araya SI; Wang HY; Matsushima K; Saida T
J Neuroimmunol; 2004 Mar; 148(1-2):192-9. PubMed ID: 14975601
[TBL] [Abstract][Full Text] [Related]
17. Regulatory effect of nicotine on the differentiation of Th1, Th2 and Th17 lymphocyte subsets in patients with rheumatoid arthritis.
Wu S; Zhou Y; Liu S; Zhang H; Luo H; Zuo X; Li T
Eur J Pharmacol; 2018 Jul; 831():38-45. PubMed ID: 29715455
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis.
Diebold M; Sievers C; Bantug G; Sanderson N; Kappos L; Kuhle J; Lindberg RLP; Derfuss T
J Autoimmun; 2018 Jan; 86():39-50. PubMed ID: 28958667
[TBL] [Abstract][Full Text] [Related]
19. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M
Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199
[TBL] [Abstract][Full Text] [Related]
20. Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile.
Medina S; Villarrubia N; Sainz de la Maza S; Lifante J; Costa-Frossard L; Roldán E; Picón C; Álvarez-Cermeño JC; Villar LM
Mult Scler; 2018 Sep; 24(10):1317-1327. PubMed ID: 28653862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
